Key points
- Claim 1 as granted reads: "Use of a whitening dentifrice composition for whitening a tooth surface in a human or animal, wherein the whitening dentifrice composition comprises: a blue dye; [and] a zinc salt, wherein the whitening dentifrice composition provides a greater whitening benefit to a tooth surface in comparison to a dentifrice composition that does not contain the zinc salt; and an orally acceptable vehicle."
- "Independent claims 1 and 8 as granted relate to the use of a whitening dentifrice composition for whitening a tooth surface in a human or animal."
- The question is whether use claim 1 is prohibited by Art. 53(c) (note, according to G 5/83, hn.1, Art. 53(c) applies equally to claims written as use claims).
- However, "[the] whitening dentifrice composition [specified in the claim] is defined in an open manner to comprise a blue dye and a zinc salt. The defined uses of this whitening dentifrice composition [therefore] encompass embodiments in which the whitening effect, defined as the purpose of the claimed uses, results at least partially from the removal of plaque [...]. In such embodiments, the defined whitening effect is inseparably linked to the therapeutic or prophylactic effect of plaque [] removal conventionally associated with the use of a dentifrice composition, as indeed foreseen in the patent [...] These embodiments are not excluded from the scope of granted claims 1 and 8, which therefore encompass subject-matter excluded from patentability under Article 53(c) EPC."
- A bit more explanation would have been useful. I infer that the Board considers that a dentrifice composition implicitly comprises a third component, besides the dye and the zinc salt, and that this third component provides for plaque removal in use.
- See T 0290/86 ( "removal of plaque from human teeth may also be considered to be a method excluded from patentability"). See also T 2071/15: "The [dental care] product's capacity of preventing acid formation achieves the therapeutic effect of preventing [...] caries and tooth erosion."
- The auxiliary requests inserting the term "cosmetic" are not admitted under Art. 13(2) RPBA. The Board adds that: "In any case, the introduction of the term "cosmetic" is not equivalent to a disclaimer excluding therapeutic methods as envisaged in G 1/03. It is not apparent that the mere introduction of the qualification "cosmetic" is apt to overcome the objection under Article 53(c) EPC, since it does not exclude embodiments in which the whitening effect results from plaque or tartar removal."
- Possibly, the disclaimer "non-medical use" would be held unclear under Article 84.
Art. 123(3)
- The further auxiliary request with product claims has a problem under Art. 123(3): "the claims of auxiliary requests 7-11 define products for use in a method which is not directed exclusively to a therapeutic effect and may therefore not qualify as purpose-limited product claims within the meaning of Article 54(5) EPC. They are therefore directed to products, with the consequence that the manufacture of the defined products falls within their scope of protection, unlike the granted claims. Accordingly, and in line with T 1635/09 (Reasons 15.1), auxiliary requests 7-11 contravene Article 123(3) EPC."
- However, see G 2/88 hn.1: "A change of category of granted claims in opposition proceedings is not open to objection under Article 123(3) EPC, if it does not result in extension of the protection conferred by the claims as a whole, when they are interpreted in accordance with Article 69 EPC and its Protocol. In this context, the national laws of the Contracting States relating to infringement should not be considered."
- I do not find G2/88 hn.1 very easy to understand when it instructs that national law is not to be considered. Applied to the present case: how do we know that the manufacture of the product is within the "scope of protection" of a product claim, if we are not allowed to consult national patent laws? (see e.g. Art. 25(a) UPCA) ?
EPO
The link to the decision is provided after the jump.